治疗阿片类药物相关性便秘的新药:纳德米定

A new drug for treatment of opioid-induced constipation: naldemedine

阿片类药物通常会引起便秘,主要是通过激动胃肠道上的μ阿片受体所致。纳德米定为一种口服μ阿片受体拮抗剂,由Shionogi制药公司研制,于2017年3月分别在美国和日本获批,用于治疗阿片类药物相关性便秘。该药最常见的不良反应包括腹痛、腹泻及恶心等。本文从作用机制、药动学、临床疗效及安全性等方面对纳德米定进行了介绍。

Constipation is often associated with opioid treatment,primarily via activation of μ-opioid receptors in the gastrointestinal tract.As an orally active μ-opioid receptor antagonist developed by Shionogi Co.,Ltd.,naldemedine received its first global approval in the USA and Japan for the treatment of opioid-induced constipation in March 2017.Most common adverse reactions of naldemedine were abdominal pain,diarrhea,nausea and so on.This article summarized the mechanism of action,pharmacokinetics,clinical efficacy,safety and adverse reactions of naldemedine.